Proposed by the EPA section on Addictive Behaviours - Rational strategies for the transfer of innovative drug targets from animal lab to clinical routine are still scarce in research and treatment of alcohol addiction. Drug development has been shown to be successful if innovative pathways are targeted in pre-clinical studies, but only if it is additionally accompanied by an innovative clinical treatment regime. In order to foster discussion and to define requirements regarding treatment targets, translationally applicable read-outs, and useful interventions we have assembled an expert group that will introduce novel concepts of innovative treatment targets and recent treatment strategies in alcohol-use disorders. Anne R Lingford-Hughes will present an overview on the neurobiological basis of alcohol addiction and principles of relapse prevention treatment; especially those that aim to reduce reward anticipation. The role of oxytocin neurotransmitter systems in addictive behaviour with a focus on recent imaging genetics studies will be the topic of the talk of Patrick Bach in order to define it as a potential future treatment target. Lofti Khemiri agreed to present data of a recently finished project focussing on the role of cognitive function in relapse prevention and associated pharmacological treatment options. At least Benjamin Rolland presents data on the experiences with baclofen in AUD treatment in France highlighting the difficult interpenetration between evidence-based medicine on the one hand, and on-the-ground practice on the other hand.